1. Home
  2. EQS vs INAB Comparison

EQS vs INAB Comparison

Compare EQS & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Equus Total Return Inc.

EQS

Equus Total Return Inc.

HOLD

Current Price

$1.20

Market Cap

16.2M

Sector

Finance

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$0.98

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EQS
INAB
Founded
1991
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.2M
13.7M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
EQS
INAB
Price
$1.20
$0.98
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
5.6K
58.0K
Earning Date
01-01-0001
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$0.90
52 Week High
$2.49
$2.73

Technical Indicators

Market Signals
Indicator
EQS
INAB
Relative Strength Index (RSI) 45.88 25.74
Support Level $1.11 N/A
Resistance Level $2.03 $1.50
Average True Range (ATR) 0.06 0.07
MACD 0.01 -0.02
Stochastic Oscillator 50.00 20.65

Price Performance

Historical Comparison
EQS
INAB

About EQS Equus Total Return Inc.

Equus Total Return Inc is a United States-based closed-end management investment company. The company invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: